{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:28:59Z","timestamp":1784658539546,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18fk0210002h0003"],"award-info":[{"award-number":["18fk0210002h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1007\/s00535-018-01543-9","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T06:09:04Z","timestamp":1546668544000},"page":"459-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir"],"prefix":"10.1007","volume":"54","author":[{"given":"Hayato","family":"Uemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kouyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Tomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS ONE. 2014;9:e112647.","journal-title":"PLoS ONE"},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00535-015-1106-8","volume":"51","author":"Y Uchida","year":"2016","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol. 2016;51:260\u201370.","journal-title":"J Gastroenterol"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/hepr.12673","volume":"46","author":"Y Uchida","year":"2016","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. Development of rare RAVs that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy via a two-hit mechanism. Hepatol Res. 2016;46:1234\u201346.","journal-title":"Hepatol Res"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/hepr.12882","volume":"47","author":"Y Uchida","year":"2017","unstructured":"Uchida Y, Kouyama JI, Naiki K, et al. \u201cReversi-type virologic failure\u201d involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017;47:1397\u2013407.","journal-title":"Hepatol Res"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"E372","DOI":"10.1111\/hepr.12977","volume":"48","author":"H Kurata","year":"2018","unstructured":"Kurata H, Uchida Y, Kouyama J, et al. A case of chronic hepatitis caused by hepatitis C virus exhibiting a discrepancy between serogroup and genotype because of inter-genotypic 2b\/1b recombination: a pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2018;48:E372\u20138.","journal-title":"Hepatol Res"},{"key":"1543_CR7","first-page":"e065339","volume":"10","author":"J Itakura","year":"2016","unstructured":"Itakura J, Kurosaki M, Hasebe C, et al. Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure. PLoS ONE. 2016;10:e065339.","journal-title":"PLoS ONE"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/hepr.12980","volume":"48","author":"H Uemura","year":"2018","unstructured":"Uemura H, Uchida Y, Kouyama JI, et al. Retreatment with sofosbuvir\/ledipasvir with or without lead-in interferon-\u03b2 injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir\/asunaprevir therapy. Hepatol Res. 2018;48:233\u201343.","journal-title":"Hepatol Res"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR10","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1128\/AAC.02494-12","volume":"57","author":"C Wang","year":"2013","unstructured":"Wang C, Sun JH, O\u2019Boyle DR 2nd, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57:2054\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/jmv.24767","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89:1248\u201354.","journal-title":"J Med Virol"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557\u201365.","journal-title":"J Gastroenterol"},{"key":"1543_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29510","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018. https:\/\/doi.org\/10.1002\/hep.29510.","journal-title":"Hepatology"},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53:566\u201375.","journal-title":"J Gastroenterol"},{"key":"1543_CR15","first-page":"62","volume":"21","author":"TI Ng","year":"2017","unstructured":"Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother. 2017;21:62.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR16","first-page":"61","volume":"24","author":"TI Ng","year":"2017","unstructured":"Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;24:61.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR17","unstructured":"Gilead Sciences HARVONI combination tablets\u00ae (sofosbuvir\u2009+\u2009ledipasvir), for oral use: PRESCRIBING INFORMATION. 2015."},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jmv.25278","volume":"91","author":"N Akuta","year":"2019","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. J Med Virol. 2019;91:102\u20136.","journal-title":"J Med Virol"},{"key":"1543_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1520-9","author":"M Osawa","year":"2018","unstructured":"Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol. 2018. https:\/\/doi.org\/10.1007\/s00535-018-1520-9.","journal-title":"J Gastroenterol."},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/AAC.02193-12","volume":"57","author":"KA Wong","year":"2013","unstructured":"Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.04226-14","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979\u201387.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00535-017-1328-z","volume":"52","author":"G Suda","year":"2017","unstructured":"Suda G, Ogawa K, Yamamoto Y, et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122\u20139.","journal-title":"J Gastroenterol"},{"key":"1543_CR23","first-page":"62","volume":"25","author":"P Krishnan","year":"2018","unstructured":"Krishnan P, Schnell G, Tripathi R, et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;25:62.","journal-title":"Antimicrob Agents Chemother"},{"key":"1543_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/hep.29836","volume":"68","author":"A Doi","year":"2018","unstructured":"Doi A, Hikita H, Sakamori R, et al. Nonstructural protein 5A\/P32 deletion after failure of ledipasvir\/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology. 2018;68:380\u20133.","journal-title":"Hepatology"},{"key":"1543_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.04.005","author":"Y Teraoka","year":"2018","unstructured":"Teraoka Y, Uchida T, Imamura M, et al. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun. 2018. https:\/\/doi.org\/10.1016\/j.bbrc.2018.04.005.","journal-title":"Biochem Biophys Res Commun"},{"key":"1543_CR26","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134\u201346.","journal-title":"N Engl J Med"},{"key":"1543_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/hep.29256","volume":"66","author":"EJ Gane","year":"2017","unstructured":"Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24\u00a0weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017;66:1083\u20139.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-01543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-018-01543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-01543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:52:47Z","timestamp":1659055967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-018-01543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-01543-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"5 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}